Comparative Pharmacology
Head-to-head clinical analysis: MARPLAN versus TRANYLCYPROMINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MARPLAN versus TRANYLCYPROMINE SULFATE.
MARPLAN vs TRANYLCYPROMINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible, non-selective monoamine oxidase inhibitor (MAOI) that increases synaptic concentrations of monoamine neurotransmitters (serotonin, norepinephrine, dopamine, tyramine) by inhibiting their oxidative deamination.
Irreversible inhibitor of monoamine oxidase (MAO-A and MAO-B), thereby increasing synaptic concentrations of monoamines (e.g., serotonin, norepinephrine, dopamine).
10 mg orally 3 times daily initially, increased to 20 mg 3 times daily; maintenance 10-20 mg 3 times daily.
Adults: 10 mg orally twice daily, increasing if necessary after 2 weeks to 30 mg/day in divided doses; maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life ranges from 2.5 to 4 hours, but due to irreversible inhibition of monoamine oxidase (MAO), the pharmacodynamic effect persists for up to 2-3 weeks after discontinuation until new enzyme synthesis occurs.
The terminal elimination half-life is approximately 2 hours (range 1.5–3 hours). However, MAO inhibition persists for 7–14 days after discontinuation due to irreversible enzyme binding.
Primarily renal excretion of metabolites, with less than 1% excreted unchanged; approximately 60-70% of a dose is recovered in urine within 24 hours, mainly as isocarboxazide metabolites; minor biliary/fecal elimination accounts for the remainder.
Renal excretion of metabolites (primarily as conjugates) accounts for approximately 90% of elimination, with less than 1% excreted unchanged in urine. Fecal excretion is minimal.
Category C
Category C
MAOI Antidepressant
MAOI Antidepressant